Advertisement

The skin and hypercoagulable states

Published:April 11, 2013DOI:https://doi.org/10.1016/j.jaad.2013.01.043
      Hypercoagulable states (HS) are inherited or acquired conditions that predispose an individual to venous and/or arterial thrombosis. The dermatologist can play a vital role in diagnosing a patient's HS by recognizing the associated cutaneous manifestations, such as purpura, purpura fulminans, livedo reticularis, livedo vasculopathy (atrophie blanche), anetoderma, chronic venous ulcers, and superficial venous thrombosis. The cutaneous manifestations of HS are generally nonspecific, but identification of an abnormal finding can warrant a further workup for an underlying thrombophilic disorder. This review will focus on the basic science of hemostasis, the evaluation of HS, the skin manifestations associated with hypercoagulability, and the use of antiplatelet and anticoagulant therapy in dermatology.

      Key words

      Abbreviations used:

      APC (activated protein C), APLA (antiphospholipid antibody), APLS (antiphospholipid antibody syndrome), CVU (chronic venous ulceration), DIC (disseminated intravascular coagulation), DVT (deep venous thrombosis), HIT (heparin-induced thrombocytopenia), HS (hypercoagulable states), LMWH (low-molecular-weight heparin), LR (livedo reticularis), LV (livedo vasculopathy), PE (pulmonary embolism), PF (purpura fulminans), SVT (superficial venous thrombosis), TF (tissue factor), TTP (thrombotic thrombocytopenic purpura), VTE (venous thromboembolism)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Davie E.M.
        • Ratnoff O.D.
        Waterfall sequence for intrinsic blood clotting.
        Science. 1964; 145: 1310-1312
        • Macfarlane R.G.
        An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier.
        Nature. 1964; 202: 498-499
        • Hoffman M.
        • Monroe D.M.
        A cell-based model of hemostasis.
        Thromb Haemost. 2001; 85: 958-965
        • Hoffman M.
        A cell-based model of coagulation and the role of factor VIIa.
        Blood Rev. 2003; 17: S1-S5
        • Hoffman M.
        Remodeling the blood coagulation cascade.
        J Thromb Thrombolysis. 2003; 16: 17-20
        • Dahlback B.
        Advances in understanding pathogenic mechanisms of thrombophilic disorders.
        Blood. 2008; 112: 19-27
        • Turpie A.G.
        • Esmon C.
        Venous and arterial thrombosis–pathogenesis and the rationale for anticoagulation.
        Thromb Haemost. 2011; 105: 586-596
        • Ho W.K.
        • Hankey G.J.
        • Quinlan D.J.
        • Eikelboom J.W.
        Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.
        Arch Intern Med. 2006; 166: 729-736
        • Bertina R.M.
        • Koeleman B.P.
        • Koster T.
        • Rosendaal F.R.
        • Dirven R.J.
        • de Ronde H.
        • et al.
        Mutation in blood coagulation factor V associated with resistance to activated protein C.
        Nature. 1994; 369: 64-67
        • van der Meer F.J.
        • Koster T.
        • Vandenbroucke J.P.
        • Briet E.
        • Rosendaal F.R.
        The Leiden thrombophilia study (LETS).
        Thromb Haemost. 1997; 78: 631-635
        • Friedman T.
        • O'Brien Coon D.
        • Michaels V.J.
        • Bontempo F.
        • Young V.L.
        • Clavijo J.A.
        • et al.
        Hereditary coagulopathies: practical diagnosis and management for the plastic surgeon.
        Plast Reconstr Surg. 2010; 125: 1544-1552
        • Poort S.R.
        • Rosendaal F.R.
        • Reitsma P.H.
        • Bertina R.M.
        A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
        Blood. 1996; 88: 3698-3703
        • Franco R.F.
        • Trip M.D.
        • ten Cate H.
        • van den Ende A.
        • Prins M.H.
        • Kastelein J.J.
        • et al.
        The 20210 G→A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease.
        Br J Haematol. 2001; 104: 50-54
        • den Heijer M.
        • Lewington S.
        • Clarke R.
        Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis.
        J Thromb Haemost. 2005; 3: 292-299
        • Tait R.C.
        • Walker I.D.
        • Perry D.J.
        • Islam S.I.
        • Daly M.E.
        • McCall F.
        • et al.
        Prevalence of antithrombin deficiency in the healthy population.
        Br J Haematol. 1994; 87: 106-112
        • Price V.E.
        • Ledingham D.L.
        • Krumpel A.
        • Chan A.K.
        Diagnosis and management of neonatal purpura fulminans.
        Semin Fetal Neonatal Med. 2011; 16: 318-322
        • Heit J.A.
        • Silverstein M.D.
        • Mohr D.N.
        • Petterson T.M.
        • O'Fallon W.M.
        • Melton III, L.J.
        Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.
        Arch Intern Med. 2000; 160: 809-815
        • Geerts W.H.
        • Code K.I.
        • Jay R.M.
        • Chen E.
        • Szalai J.P.
        A prospective study of venous thromboembolism after major trauma.
        N Engl J Med. 1994; 331: 1601-1606
        • Mertens I.
        • Van Gaal L.F.
        Obesity, hemostasis and the fibrinolytic system.
        Obes Rev. 2002; 3: 85-101
        • Eckel R.H.
        • Krauss R.M.
        American Heart Association call to action: obesity as a major risk factor for coronary artery disease.
        Circulation. 1998; 97: 2099-2100
        • Winkler U.H.
        Obesity and hemostasis.
        Arch Gynecol Obstet. 1997; 261: 25-29
        • Bodary P.F.
        • Westrick R.J.
        • Wickenheiser K.J.
        • Shen Y.
        • Eitzman D.T.
        Effect of leptin in arterial thrombosis following vascular injury in mice.
        JAMA. 2002; 287: 1706-1709
        • Furie B.
        • Furie B.C.
        Mechanisms of thrombus formation.
        N Engl J Med. 2008; 359: 938-949
        • Kyriazi V.
        Breast cancer as an acquired thrombophilic state.
        J Breast Cancer. 2012; 15: 148-156
        • Falanga A.
        Thrombophilia in cancer.
        Semin Thromb Hemost. 2005; 31: 104-110
        • Sousou T.
        • Khorama A.A.
        New insights into cancer-associated thrombosis.
        Arterioscler Thromb Vasc Biol. 2009; 29: 316-320
        • Kuter D.J.
        Thrombotic complications of central venous catheters in cancer patients.
        Oncologist. 2004; 9: 207-216
        • Mandala M.
        • Curigliano G.
        • Bucciarelli P.
        • Ferretti G.
        • Mannucci P.M.
        • Colleoni M.
        • et al.
        Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.
        Ann Oncol. 2004; 15: 590-593
        • Khorana A.A.
        • Connolly G.C.
        Assessing risk of venous thrombosis in the patient with cancer.
        J Clin Oncol. 2009; 27: 4839-4847
        • Anderson B.S.
        • Steffensen F.H.
        • Sorensen H.T.
        • Nielsen G.L.
        • Olsen J.
        The cumulative incidence of venous thromboembolism during pregnancy and puerperium.
        Acta Obstet Gynecol Scand. 1998; 77: 170-173
        • Jacobsen A.F.
        • Sandset P.M.
        Venous thromboembolism associated with pregnancy and hormonal therapy.
        Best Pract Res Clin Haematol. 2012; 25: 319-332
        • Gray G.
        • Nelson-Piercy C.
        Thromboembolic disorders in obstetrics.
        Best Pract Res Clin Obstet Gynaecol. 2012; 26: 53-64
        • Rosenkranz A.
        • Hiden M.
        • Leschnik B.
        • Weiss E.
        • Schlembach D.
        • Lang U.
        • et al.
        Calibrated automated thrombin generation in normal uncomplicated pregnancy.
        Thromb Haemost. 2008; 99: 331-337
        • Darmstadt G.L.
        Acute infectious purpura fulminans: pathogenesis and medical management.
        Pediatr Dermatol. 1998; 15: 169-183
        • Chalmers E.
        • Cooper P.
        • Forman K.
        • Grimley C.
        • Khair K.
        • Minford A.
        • et al.
        Purpura fulminans: recognition, diagnosis and management.
        Arch Dis Child. 2011; 96: 1066-1071
        • Kremer Hovinga J.A.
        • Lammle B.
        Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
        Hematology Am Soc Hematol Educ Program. 2012; 2012: 610-616
        • Sadler J.E.
        Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
        Blood. 2008; 112: 11-18
        • Nazarian R.M.
        • Van Cott E.M.
        • Zembowicz A.
        • Duncan L.M.
        Warfarin-induced skin necrosis.
        J Am Acad Dermatol. 2009; 61: 325-332
        • Amiral J.
        • Bridey F.
        • Dreyfus M.
        • Vissoc A.M.
        • Fressinaud E.
        • Wolf M.
        • et al.
        Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.
        Thromb Haemost. 1992; 68: 95-96
        • Prechel M.
        • Walenga J.M.
        Heparin-induced thrombocytopenia: an update.
        Semin Thromb Hemost. 2012; 38: 483-496
        • Greinacher A.
        • Alban S.
        • Omer-Adam M.A.
        • Weitschies W.
        • Warkentin T.E.
        Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight-heparin, and fondaparinux in different clinical settings.
        Thromb Res. 2008; 122: 211-220
        • Pouplard C.
        • Couvret C.
        • Regina S.
        • Gruel Y.
        Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux.
        J Thromb Haemost. 2005; 3: 2813-2815
        • Fine A.
        • Zacharias J.
        Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy.
        Kidney Int. 2002; 61: 2210-2217
        • Harris R.J.
        • Cropley T.G.
        Possible role of hypercoagulability in calciphylaxis: review of the literature.
        J Am Acad Dermatol. 2011; 64: 405-412
        • Kuba Y.
        • Terao H.
        • Takahara M.
        • Kiryu H.
        • Furue M.
        Case of proximal calciphylaxis with protein S deficiency treated with multimodality therapy.
        J Dermatol. 2012; 39: 657-659
        • Kerk N.
        • Meyer V.
        • Goerge T.
        Calciphylaxis induced by acquired protein S deficiency in a patient with multiple myeloma–effective treatment with low-molecular-weight heparin.
        J Dtsch Dermatol Ges. 2012; 10: 518-519
        • Perez-Mijares R.
        • Guzman-Zamudio J.
        • Payan-Lopez J.
        • Rodriguez-Fernandez A.
        • Almarez-Jimenez M.
        Calciphylaxis in a hemodialysis patient: functional protein S deficiency?.
        Nephrol Dial Transplant. 1996; 11: 1856-1859
        • Rostaing L.
        • el Feki S.
        • Delisle M.
        • Duran-Malgouyres C.
        • Ton-That H.
        • Bonafe J.
        • et al.
        Calciphylaxis in a chronic hemodialysis patient with protein S deficiency.
        Am J Nephrol. 1995; 15: 524-527
        • Wong J.
        • Laumann A.
        • Martinez M.
        Calciphylaxis and antiphospholipid antibody syndrome.
        J Am Acad Dermatol. 2000; 42: 849
        • Nigwekar S.
        • Wolf M.
        • Sterns R.
        • Hix J.
        Calciphylaxis from nonuremic causes: a systematic review.
        Clin J Am Soc Nephrol. 2008; 3: 1139-1143
        • Chavel S.
        • Taraszka K.
        • Schaffer J.
        • Lazova R.
        • Schechner J.
        Calciphylaxis associated with acute, reversible renal failure in setting of alcoholic cirrhosis.
        J Am Acad Dermatol. 2004; 50: S125-S128
        • Goli A.
        • Goli S.
        • Shah L.
        • Byrd R.
        • Roy M.
        Calciphylaxis: a rare association with alcoholic cirrhosis. Are deficiencies in protein C and S the cause?.
        South Med J. 2005; 98: 736-739
        • Goyal S.
        • Huhn K.
        • Provost T.
        Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible etiological role of chemotherapy.
        Br J Dermatol. 2008; 143: 1087-1090
        • Korkmaz C.
        • Dundar E.
        • Zubaroglu I.
        Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency.
        Clin Rheumatol. 2002; 21: 66-69
        • Coates T.
        • Kirkland G.
        • Dymock R.
        • Murphy B.
        • Brealey J.
        • Methew T.
        • et al.
        Cutaneous necrosis from calcific uremic arteriolopathy.
        Am J Kidney Dis. 1998; 32: 384-391
        • Sewell L.
        • Weenig R.
        • Davis M.
        • McEvoy M.
        • Pittelkow M.
        Low-dose tissue plasminogen activator for calciphylaxis.
        Arch Dermatol. 2004; 140: 1045-1048
        • Meroni P.L.
        • Borghi M.O.
        • Raschi E.
        • Tedesco F.
        Pathogenesis of antiphospholipid syndrome: understanding the antibodies.
        Nature. 2011; 7: 330-339
        • Miyakis S.
        • Lockshin M.D.
        • Atsumi T.
        • Branch D.W.
        • Brey R.L.
        • Cervera R.
        • et al.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J Thromb Haemost. 2006; 4: 295-306
        • Cervera R.
        • Espinosa G.
        Update on the catastrophic antiphospholipid syndrome and the CAPS registry.
        Semin Thromb Hemost. 2012; 38: 333-338
        • Hodak E.
        • David M.
        Primary anetoderma and antiphospholipid antibodies–review of the literature.
        Clin Rev Allergy Immunol. 2007; 32: 162-166
        • Venhoff N.
        • Miehle N.
        • Juttner E.
        • Peter H.H.
        • Walker U.A.
        Clinical images: anetoderma in systemic lupus erythematosus with antiphospholipid antibodies.
        Arthritis Rheum. 2005; 52: 2228
        • Bilen N.
        • Bayamgurler D.
        • Sikar A.
        • Ercin C.
        • Yilmaz A.
        Anetoderma associated with antiphospholipid syndrome and systemic lupus erythematosus.
        Lupus. 2003; 12: 714-716
        • Sabio J.M.
        • Tercedor J.
        • Massare E.
        • Jimenez-Alonso J.
        Anetoderma associated with systemic lupus erythematosus and antiphospholipid antibodies.
        Lupus. 2004; 13: 826-827
        • Disdier P.
        • Harle J.R.
        • Andrac L.
        • Verrot D.
        • Bolla G.
        • San Marco M.
        • et al.
        Primary anetoderma associated with the antiphospholipid syndrome.
        J Am Acad Dermatol. 1994; 30: 133-134
        • Sparsa A.
        • Piette J.C.
        • Wechsler B.
        • Amoura Z.
        • Frances C.
        Anetoderma and its prothrombotic abnormalities.
        J Am Acad Dermatol. 2003; 49: 1008-1012
        • de Souza E.M.
        • Daldon P.E.
        • Cintra M.L.
        Anetoderma associated with primary antiphospholipid syndrome.
        J Am Acad Dermatol. 2007; 56: 881-882
        • Romani J.
        • Perez F.
        • Llobet M.
        • Planaquma M.
        • Pujol R.M.
        Anetoderma associated with the antiphospholipid antibodies: case report and review of the literature.
        J Eur Acad Dermatol Venereol. 2001; 15: 175-178
        • Montilla C.
        • Alarcon-Segovia D.
        Anetoderma in systemic lupus erythematosus: relationship to antiphospholipid antibodies.
        Lupus. 2000; 9: 545-547
        • Fernandez-Galar M.
        • Espana A.
        • Lloret P.
        Systemic lupus erythematosus-associated anetoderma and anti-phospholipid antibodies.
        Clin Exp Dermatol. 2003; 28: 39-42
        • Hodak E.
        • Feureman H.
        • Molad Y.
        • Monselise Y.
        • David M.
        Primary anetoderma: a cutaneous sign of antiphospholipid antibodies.
        Lupus. 2003; 12: 564-568
        • Clark E.R.
        • English J.C.
        Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency.
        J Am Acad Dermatol. 2011; 65: 880-881
        • Gibbs M.B.
        • English J.C.
        • Zirwas M.J.
        Livedo reticularis: an update.
        J Am Acad Dermatol. 2005; 52: 1009-1019
        • Weinstein C.
        • Miller M.H.
        • Axtens R.
        • Buchanan R.
        • Littlejohn G.O.
        Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus.
        Arch Dermatol. 1987; 123: 596-600
        • Golden R.L.
        Livedo reticularis in systemic lupus erythematosus.
        Arch Dermatol. 1963; 87: 299-301
        • Uthman I.W.
        • Khamashta M.A.
        Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome.
        J Rheumatol. 2006; 33: 2379-2382
        • Frances C.
        • Niang S.
        • Laffitte E.
        • Pelletier F.I.
        • Costedoat N.
        • Piette J.C.
        Dermatologic manifestations of the antiphospholipid syndrome.
        Arthritis Rheum. 2005; 52: 1785-1793
        • Browning C.E.
        • Callen J.P.
        Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia.
        Arch Dermatol. 2006; 142: 75-78
        • Hairston B.R.
        • Davis M.D.
        • Pittelkow M.R.
        • Ahmed I.
        Livedoid vasculopathy: further evidence for procoagulant pathogenesis.
        Arch Dermatol. 2006; 142: 1413-1418
        • Criado P.R.
        • Rivitti E.A.
        • Sotto M.N.
        • de Carvalho J.F.
        Livedoid vasculopathy as a coagulation disorder.
        Autoimmun Rev. 2011; 10: 353-360
        • Biedermann T.
        • Flaig M.J.
        • Sander C.A.
        Livedoid vasculopathy in a patient with factor V mutation (Leiden).
        J Cutan Pathol. 2000; 27: 410-412
        • Calamia K.T.
        • Balabanova M.
        • Perniciaro C.
        • Walsh J.S.
        Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation.
        J Am Acad Dermatol. 2002; 46: 133-137
        • Lewerenz V.
        • Burchardt T.
        • Buchau A.
        • Ruzicka T.
        • Megahed M.
        Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome.
        Hautarzt. 2004; 55: 379-381
        • Gotlib J.
        • Kohler S.
        • Reicherter P.
        • Oro A.E.
        • Zehnder J.L.
        Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis.
        Arch Dermatol. 2003; 139: 1081-1083
        • Anavekar N.S.
        • Kelly R.
        Heterozygous prothrombin gene mutation associated with livedoid vasculopathy.
        Australas J Dermatol. 2007; 48: 120-123
        • Hegemann B.
        • Helmbold P.
        • Marsch W.C.
        Livedoid vasculitis with ulcerations: the role of antithrombin III deficiency and its therapeutic consequences.
        Arch Dermatol. 2002; 138: 841-842
        • Boyvat A.
        • Kundakci N.
        • Babikir M.O.
        • Gurgey E.
        Livedoid vasculopathy associated with heterozygous protein C deficiency.
        Br J Dermatol. 2000; 143: 840-842
        • Baccard M.
        • Vignon-Pennamen M.D.
        • Janier M.
        Livedo vasculitis with protein C system deficiency.
        Arch Dermatol. 1992; 128: 1410-1411
        • Khenifer S.
        • Thomas L.
        • Balme B.
        • Dalle S.
        Livedoid vasculitis associated with double heterozygous factor V Leiden and prothrombin G20210A gene mutations.
        Clin Exp Dermatol. 2009; 34: e811-e813
        • Wakelin S.H.
        • Ellis J.P.
        • Black M.M.
        Livedoid vasculitis with anticardiolipin antibodies: improvement with danazol.
        Br J Dermatol. 1998; 139: 935-937
        • Grob J.J.
        • Bonerandi J.J.
        Thrombotic skin disease as a marker of the anticardiolipin syndrome: livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity.
        J Am Acad Dermatol. 1989; 20: 1063-1069
        • Acland K.M.
        • Darvay A.
        • Wakelin S.H.
        • Russell-Jones R.
        Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?.
        Br J Dermatol. 1999; 140: 131-135
        • Meiss F.
        • Marsch W.C.
        • Fischer M.
        Livedoid vasculopathy: the role of hyperhomocysteinemia and its simple therapeutic consequences.
        Eur J Dermatol. 2006; 16: 159-162
        • Gibson G.E.
        • Li H.
        • Pittelkow M.R.
        Homocysteinemia and livedoid vasculitis.
        J Am Acad Dermatol. 1999; 40: 279-281
        • Rampf J.
        • Sunderkotter C.
        • Hirschfeld G.
        • Scharffetter-Kochanek K.
        • Weiss J.M.
        Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinemia in a patient with livedo vasculopathy: treatment with vitamin supplementation and low weight molecular heparin.
        Br J Dermatol. 2006; 155: 850-852
        • Wiszniewski A.
        • Bykowska K.
        • Bilski R.
        • Jaskowiak W.
        • Proniewski J.
        Prevalence rate for inherited thrombophilia in patients with chronic and recurrent venous leg ulceration.
        Wound Repair Regen. 2011; 19: 552-558
        • Mackenzie R.K.
        • Ludlam C.A.
        • Ruckley C.V.
        • Allan P.L.
        • Burns P.
        • Bradbury A.W.
        The prevalence of thrombophilia in patients with chronic venous leg ulceration.
        J Vasc Surg. 2002; 35: 718-722
        • Binder B.
        • Lackner H.K.
        • Salmhofer W.
        • Kroemer S.
        • Custovic J.
        • Hofmann-Wellenhof R.
        Association between superficial vein thrombosis and deep vein thrombosis of the lower extremities.
        Arch Dermatol. 2009; 145: 753-757
        • Decousus H.
        • Quere I.
        • Presles E.
        • Becker F.
        • Barrellier M.T.
        • Chanut M.
        • et al.
        POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial vein thrombosis and venous thromboembolism: a large prospective epidemiologic study.
        Ann Intern Med. 2010; 152: 218-224
        • Galanaud J.P.
        • Genty C.
        • Sevestre M.A.
        • Brisot D.
        • Lausecker M.
        • Gillet J.L.
        • et al.
        Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis: the OPTIMEV study.
        Thromb Haemost. 2011; 105: 31-39
        • Carnero-Vidal L.G.
        • Rathbun S.
        • Wakefield T.W.
        Anticoagulant treatment for superficial venous thrombosis.
        Dis Mon. 2010; 56: 574-581
        • Decousus H.
        • Frappe P.
        • Accassat S.
        • Bertoletti L.
        • Buchmuller A.
        • Seffert B.
        • et al.
        Epidemiology, diagnosis, treatment and management of superficial-vein thrombosis of legs.
        Best Pract Res Clin Haematol. 2012; 25: 275-284
        • Leon L.R.
        • Labropoulos N.
        Superficial vein thrombosis and hypercoagulable states: the evidence.
        Perspect Vasc Surg Endovasc Ther. 2005; 17: 43-46
        • de Godoy J.M.
        • Batigalia F.
        • Braile D.M.
        Superficial vein thrombosis and anticardiolipin antibodies–report of association.
        Angiology. 2001; 52: 127-129
        • de Godoy J.
        • Braile D.M.
        Protein S deficiency in repetitive superficial thrombosis.
        Clin Appl Thromb Hemost. 2003; 9: 61-62
        • Hanson J.N.
        • Ascher E.
        • DePippo P.
        • Lorensen E.
        • Scheinman M.
        • Yorkovich W.
        • et al.
        Saphenous vein thrombosis (SVT): a deceptively benign disease.
        J Vasc Surg. 1998; 27: 677-680
        • de Moerloose P.
        • Wutschert R.
        • Heinzmann M.
        • Perneger T.
        • Reber G.
        • Bounameaux H.
        Superficial vein thrombosis of the lower limb: influence of factor V Leiden, factor G20210A and overweight.
        Thromb Haemost. 1998; 80: 239-241
        • Martinelli I.
        • Cattaneo M.
        • Taioli E.
        • De Stefano V.
        • Chiusolo P.
        • Mannucci P.M.
        Genetic risk factors for superficial vein thrombosis.
        Thromb Haemost. 1999; 82: 1215-1217
        • Hairston B.R.
        • Davis M.D.
        • Gibson L.E.
        • Drage L.A.
        Treatment of livedoid vasculopathy with low-molecular-weight-heparin: report of two cases.
        Arch Dermatol. 2003; 139: 987-990
        • Di Giacomo T.B.
        • Hussein T.P.
        • Souza D.G.
        • Criado P.R.
        Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anti-coagulant drugs–a prospective study.
        J Eur Acad Dermatol Venereol. 2010; 24: 1340-1346
        • Kerk N.
        • Drabik A.
        • Luger T.
        • Schneider S.
        • Goerge T.
        Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
        Br J Dermatol. 2013; 168: 898-899
        • Abou Rahal J.
        • Ishak R.S.
        • Otrock Z.K.
        • Kibbi A.G.
        • Taher A.T.
        Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.
        J Thromb Thrombolysis. 2012; 34: 541-544
        • Kavala M.
        • Kocaturk E.
        • Zindanci I.
        • Turkoglu Z.
        • Altintas S.
        A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin.
        J Dermatolog Treat. 2008; 19: 121-123
        • Davis M.D.
        • Wysokinski W.E.
        Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: response to warfarin.
        J Am Acad Dermatol. 2008; 58: 512-515
        • Levine J.S.
        • Branch D.W.
        • Rauch J.
        The antiphospholipid syndrome.
        N Engl J Med. 2002; 346: 752-763
        • Decousus H.
        • Prandoni P.
        • Mismetti P.
        • Bauersachs R.M.
        • Boda Z.
        • Brenner B.
        • et al.
        Fondaparinux in the treatment of superficial-vein thrombosis in the legs.
        N Engl J Med. 2010; 363: 1222-1232
        • Cosmi B.
        • Filippini M.
        • Tonti D.
        • Avruscio G.
        • Ghirarduzzi A.
        • Bucherinin E.
        • et al.
        A randomized double-blind study of low-molecular weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (superficial thromboembolism and Fluxum).
        J Thromb Haemost. 2012; 10: 1026-1035
        • Di Nisio M.
        • Wicher I.M.
        • Middeldorp S.
        Treatment for superficial thrombophlebitis of the leg.
        Cochrane Database Syst Rev. 2012; 3 ([review]): CD004982
        • Kearon C.
        • Akl E.A.
        • Comerota A.J.
        • Prandoni P.
        • Bounameaux H.
        • Goldhaber S.Z.
        • et al.
        Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e419-e494S